glp 1 novo Novo's Wegovy becomes first GLP-1 drug approved for MASH GLP-1 Drug Fails to Quell

The paraventricular hypothalamus regulates satiety and prevents obesity via two genetically distinct circuits

Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study

Note : Approximately 70% of American adults are overweight or obese

Data submitting to ICSRs with GLP-1 RAs as suspected drugs were extracted from the FAERS database spanning the period between January 2005 and September 2023

After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more

McIntyre, R